Pfizer Unit Gets FDA Approval for Tivdak in Cervical Cancer

Seagen, a recent acquisition of Pfizer, got FDA traditional approval for Tivdak (tisotumab vedotin-tftv) in recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

• Tisotumab previously got accelerated approval for the same indication
• Application was also granted priority review

To view the source of this information, click here

To contact the reporter on this story:
Cameron Baker in New York at cbaker225@bloomberg.net

To contact the editor responsible for this story:
Sunil Kesur at skesur@bloomberg.net

© 2024 Bloomberg L.P. All rights reserved. Used with permission.